| Bioactivity | Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment. |
| Invitro | APDS 突变体 p110δ 在细胞系和患者来源的淋巴细胞中的表达导致通路活性增加，以 AKT 或 S6 的磷酸化来衡量。而 Leniolisib phosphate 以浓度依赖性方式抑制该通路活性[1]。 |
| Name | Leniolisib phosphate |
| CAS | 1354691-97-6 |
| Formula | C21H28F3N6O6P |
| Molar Mass | 548.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406 [2]. Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8(9):975-980. |
Leniolisib phosphate
CAS: 1354691-97-6 F: C21H28F3N6O6P W: 548.45
Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for imm
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.